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Introduction
Obesity is a well-known independent risk factor 
for cardiovascular disease (CVD) and is strongly 
associated with the development of other CVD 
risk factors, including hypertension, dyslipidaemia, 
glucose intolerance and overt diabetes.1 As such, 
weight loss is encouraged to reduce cardiovascular 
risk in both healthy overweight individuals and those 
at high cardiovascular risk, including patients with 
diabetes.2-5 Therefore, it is surprising that, although the 
association between obesity and the initial incidence 
of a cardiovascular (CV) event is well established, 
numerous studies have found that overweight patients 
who survive a first CV event are less likely to experience 
a second event.6-16 Similarly among diabetic subjects, 
some studies have suggested that obesity may be 
protective for, or at least non-contributory to an adverse 
CVD outcome; whereas leaner, normal weight patients 
apparently have an elevated risk for CVD death.17-24 
This ‘obesity paradox’ seems not only contrary to what 
common sense might suggest, but causes confusion 
when considering how to advise patients about weight 
management, especially when treatment itself (or non-
treatment) may be associated with changes in weight.
The obesity paradox in patients with established 
cardiovascular disease
Obesity in childhood and in adulthood is associated 
with an increased risk of coronary heart disease in 
later life.25 For example, in a long-term population-
based study of men for whom body mass index 
(BMI) data were available at age 18 years or shortly 
thereafter, nearly half of those who were obese 
(≥ 30 kg/m2) were subsequently diagnosed with type 
2 diabetes, hypertension, myocardial infarction, stroke 
or venous thromboembolism, or died before reaching 
age 55 years.26 In comparison to those with normal 
BMI (18.5 to < 25 kg/m2), the incidence of diabetes 
among obese subjects was increased eightfold; 
venous thromboembolism fourfold; and event rate for 
hypertension, myocardial infarction and premature 
death was doubled. 
Overweight and obesity are associated with early 
development and clustering of cardiovascular risk 
factors, including those characteristic of the metabolic 
syndrome (insulin resistance, high blood pressure, 
dyslipidaemia). However, the risk of myocardial 
infarction (MI) and ischaemic heart disease (IHD) is 
increased in obese people even in the absence of 
these comorbidities (Table 1).27 
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On the other hand, a growing number of studies 
indicate that, in patients who have experienced 
an initial CV event, recurrent events and mortality 
are more common among those with lower body 
weight. The International Verapamil SR/Trandolapril 
(INVEST) study was a prospective, randomised 
international study of 22 576 patients with hypertension 
and coronary artery disease (CAD), with a mean 
follow-up of 2.7 years. In comparison to patients with 
normal weight (BMI 20 to < 25 kg/m2), overweight 
patients (BMI 25-30 kg/m2) and obese patients 
(BMI ≥ 30 kg/m2), including those with class II or III obesity 
(BMI ≥ 35 kg/m2), had a 20-30% lower risk of death, 
nonfatal myocardial infarction or non-fatal stroke.14 
Kennedy and colleagues reviewed data from 3 large 
studies of patients with prior acute myocardial infarction 
(AMI) or stable CAD, namely Optimal Trial in Myocardial 
Infarction with the Angiotensin II Antagonist Losartan 
(OPTIMAAL), Cooperative New Scandinavian Enalapril 
Survival Study (CONSENSUS II) and 4S, which included 
over 12 000 patients. Weight loss, but not weight gain 
was independently associated with increased risk 
of mortality.15 In another study, among a cohort of 
4 880 consecutive patients undergoing percutaneous 
coronary intervention for CAD, compared to normal 
weight individuals, five-year survival was significantly 
better among those with BMI ≥ 27.5 and < 30 kg/m2.28 
A review of 40 cohort studies including a total of 
250 152 patients with CAD and at least 6 months follow-
up showed a U-shaped risk profile for body weight 
and cardiovascular mortality. Overweight patients 
(BMI 25-29.9 kg/m2) had the lowest risk for both total 
mortality and cardiovascular mortality, which was 12% 
lower than in those with a normal BMI.16 
Similar results have recently been demonstrated after 
acute stroke or transient ischaemic attack (TIA). Obese 
patients had a lower risk of mortality or stroke recurrence 
than those with normal weight, whereas underweight 
patients (BMI < 18.5 kg/m2) had the highest risk for all 
endpoints.10-12
The obesity paradox in patients with diabetes
The obesity paradox has been observed in diabetic 
patients with and without cardiovascular comorbidity. 
In the World Health Organization’s Multinational Study 
of Vascular Disease in Diabetes, diabetic patients 
were followed up over a 13-year period between 1975 
and 1988. Among patients with noninsulin-dependent 
diabetes (NIDDM), body weight was positively 
associated with blood pressure, age and cholesterol 
and negatively associated with duration of diabetes, 
retinopathy and use of insulin.17 Among patients with 
insulin-dependent diabetes (IDDM), body weight 
was positively associated with blood pressure and, in 
men, with cholesterol, whereas fasting blood glucose 
was higher in the most obese groups in women only.18 
Although in NIDDM there was no strong relationship 
between BMI and mortality (after adjusting for other 
risk factors), weight loss in subjects with BMI ≤ 29 kg/
m2 was associated with a 2-3-fold increase in mortality 
risk compared to those who maintained a steady 
weight. Only in the most obese subjects at baseline 
(BMI > 29 kg/m2), was weight gain associated with 
an increase in mortality risk. In patients with IDDM, 
there was an inverse “J” relationship between body 
weight and mortality, with the highest mortality rates 
among the leanest individuals. After adjustment for 
confounders, including duration of diabetes, smoking, 
proteinuria, blood pressure and cholesterol, the 
mortality rates among patients assigned to four BMI 
categories ranging from 20 to > 26 kg/m2 were similar. 
In the second Diabetes Insulin-Glucose in Acute 
Myocardial Infarction (DIGAMI 2) study, initiation or 
maintenance of insulin therapy after myocardial 
infarction in patients with diabetes was associated 
with a significant increase in weight and incidence of 
reinfarction within 12 months. However, the increase in 
weight did not explain the increased rate of reinfarction. 
The patients with the least increase in body weight 
experienced the highest CV mortality, and each 
kilogram increase in weight reduced the risk of CV 
death by approximately 6%.19 Adjustment for baseline 
Table I: Risk of myocardial infarction according to combinations of body mass index category and the presence or absence of metabolic 
syndrome27
Body mass index Metabolic syndrome Hazard ratio (95% confidence interval)
Overall Men Women
Normal weight No 1 1 1
Overweight No 1.26 (1-1.61) 1.09 (0.81-1.48) 1.62 (1.09-2.40)
Obese No 1.88 (1.34-2.63) 1.83 (1.19-2.82) 1.91 (1.12-3.27)
Normal weight Yes 1.39 (0.96-2.02) 1.14 (0.67-1.92) 1.80 (1.06-3.06)
Overweight Yes 1.70 (1.35-2.15) 1.45 (1.09-1.93) 2.26 (1.52-3.35)
Obese Yes 2.33 (1.81-3) 2.03 (1.48-2.78) 2.79 (1.83-4.25)
Body mass index category: Normal 18.5-24.9 kg/m2, overweight 25-29.9 kg/m2 and obese ≥ 30 kg/m2
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BMI, hyperlipidaemia, mean arterial pressure, smoking, 
diabetes duration and gender did not significantly alter 
the results.
In the Proactive Prospective Pioglitazone Clinical Trial 
In Macrovascular Events (PROactive trial) population 
of 5202 patients with type 2 diabetes and pre-existing 
cardiovascular comorbidity, over a mean follow-up 
duration of 35 months, the lowest mortality occurred in 
subjects with BMI 30-35 kg/m2. The rate of both mortality 
and hospitalisations were higher among patients with 
BMI 22 to < 25 kg/m2. Weight loss, but not weight gain, 
was associated with increased mortality, and weight 
gain was associated with a significantly lower risk of 
cardiovascular death. 
In a pooled analysis of 5 longitudinal cohort studies, 
(including 27 125 person years follow up), normal 
weight (18.5-< 25 kg/m2) at time of diabetes diagnosis 
was associated with a twofold risk of total mortality 
and 50% increase in the risk of cardiovascular mortality 
compared with subjects who were overweight or 
obese at diagnosis.29 
Various additional large observational studies suggest 
that diabetes in leaner patients, and those with a lower 
BMI may be associated with a higher incidence of 
CV death than in overweight or obese individuals.20-23 
In the UK Prospective Diabetes Study (UKPDS), 
despite a significant increase in weight compared 
to conventional therapy, intensive glucose control 
with insulin was associated with fewer microvascular 
complications without an increase in cardiovascular 
mortality.30 
However, there are observational studies that suggest 
that lower BMI and weight loss may be associated with 
more favourable cardiovascular outcomes.
Zoppini examined a cohort of 3398 patients with type 2 
diabetes and found that while moderate excess weight 
predicted better survival in patients older than 65 
years, in younger patients it was associated with higher 
all-cause mortality.20 Two large observational studies 
including in excess of 24 000 patients with no previous 
CVD found that both overweight and obesity at or 
after the diagnosis of diabetes independently increase 
the risk of cardiovascular disease and mortality in type 
2 diabetes.31,32 Bodegard recently reported that, in a 
cohort of 8486 newly diagnosed patients with type 
2 diabetes followed for up to 9 years, compared to 
unchanged BMI, BMI increase within the first 18 months 
of diagnosis was associated with 83% increased risk of 
CV mortality and 48% increase in all-cause mortality. 
However, BMI decrease during this time was not 
associated with reduced risk of these outcomes.33 
In contrast, in a 12-year, prospective observational 
study including 4970 overweight individuals with type 
2 diabetes aged 40-64 years of age, intentional weight 
loss was associated with a 25% reduction in total 
mortality and a 28% reduction in cardiovascular and 
diabetes-related mortality.34
Interestingly, in another prospective observational 
study including 1401 type 2 diabetics over the age 
of 35 years, compared to patients who did not try to 
lose weight, the mere intention to lose weight was 
associated with reductions in mortality regardless of 
whether weight loss actually occurred. Individuals 
who reported trying to lose weight had a 23% lower 
mortality than those who did not and this was the same 
regardless of whether attempts at weight loss were 
successful.35 These results suggest that lifestyle changes 
and behaviours associated with weight loss attempts 
may improve longevity irrespective of the degree of 
weight loss, or they may reflect that achieved weight 
loss is difficult to maintain, but nevertheless may be 
associated with improved long-term health.
The Look AHEAD Study
The Action for Health in Diabetes (Look AHEAD) study 
is the first large randomised, controlled clinical trial to 
investigate the benefits of intensive lifestyle intervention 
in patients with type 2 diabetes.36 It included 5145 
patients between the ages of 45 and 75 years of 
age (mean age 59 years), with a median duration of 
diabetes at baseline of five years. Fourteen per cent 
of patients had a previous history of CVD. The patients 
were randomised to two groups; intensive lifestyle 
intervention with the aim of achieving and maintaining 
weight loss of at least 7% through restriction of caloric 
intake and increased physical activity, or diabetes 
support and education. The primary outcome was 
a composite of death from cardiovascular causes, 
non-fatal myocardial infarction, non-atal stroke, or 
hospitalisation during a maximum follow-up of 13.5 
years. 
The study was stopped early after a median of 9.6 years 
when interim analyses demonstrated no difference 
in CV outcomes between groups and suggested 
that longer follow-up was not likely to change that 
observation. 
Despite the absence of an apparent benefit with 
regard to CV mortality, in both the Look AHEAD study 
and in Bodegard’s study, intentional weight loss was 
associated with early improvements in glycaemia, 
blood pressure, triglycerides, high density lipoprotein 
cholesterol (HDL-C) and other markers of cardiovascular 
risk, such as C-reactive protein (CRP).33,36-38 In Look 
AHEAD, although the differences were modest, 
intensive lifestyle intervention was associated with a 
significantly greater likelihood of complete or partial 
remission of type 2 diabetes during the first four years of 
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intervention.39 This effect was most marked in patients 
with substantial weight loss or fitness change, shorter 
duration of diabetes or lower HbA1c at baseline, and 
those not using insulin.
Is there an explanation for the obesity paradox?
A number of theories have been proposed to explain 
the obesity paradox and differing results of clinical 
studies.
Low body weight and weight loss may be 
indicative of poor health
In patients with diabetes, poor glucose control may 
be associated with both weight loss and an increased 
risk of diabetic-related complications.33 Therefore, in 
studies where BMI was measured after the diagnosis 
of diabetes, the initiation of diabetes treatment or 
progression of the underlying illness may account for 
poorer prognosis associated with lower BMI.32
Low BMI, independent of diabetes, may increase 
the risk of adverse outcomes. Low body weight may 
increase mortality from other comorbid disease 
(e.g. heart failure, hypertension, chronic obstructive 
airways disease), cancer, or increase risks arising as a 
complication from osteopenia-related fractures.29,40
Conversely, it is possible that in some disease states, 
rather than being harmful, overweight and even 
obesity may be protective against adverse outcomes. 
If chronic illness is a metabolically demanding state, 
survival may be better in overweight subjects who have 
greater metabolic reserves.41 This might help, at least 
partially, to explain apparent decline in overweight-
related risk that is apparent with increasing age.20 
Similarly, patients recovering from a cardiovascular 
event may benefit from greater body mass, where a 
post event catabolic state, with fever, sympathetic 
activation, endothelial and insulin sensitivity dysfunction 
leads to muscle wasting and overall weight loss.42
Differential treatment
Overweight patients may be managed differently 
to patients with a lower body weight. They may 
receive more frequent follow-up and more aggressive 
investigations and treatments. For example, it is 
conceivable that cardiovascular medications, 
including antihypertensive drugs, aspirin and statins, 
are more likely to be prescribed for overweight 
individuals and those with cardiovascular risk factors 
such as hypertension or hypercholesterolaemia.29,33,41 
In contrast, fewer cardioprotective measures may be 
used in patients who lose weight if that weight loss 
leads to improvement in modifiable CV risk factors.43 
BMI is a simplistic measurement
BMI does not account for the proportion and 
distribution of muscle, bone and adipose tissue. 
For example, while lower BMI may indicate a fit 
individual following a healthy diet, it may also be 
associated with illness and undernutrition. Conversely, 
BMI well into the overweight range may occur in fit 
individuals, such as athletes or bodybuilders. 
Insulin resistance may be an important pathogenic 
component underlying cardiovascular disease. 
Therefore, unmeasured lean mass, fat mass, fat 
distribution and insulin sensitivity may significantly 
confound the comparison of outcomes among 
individuals with a similar BMI.29 In addition to fat mass, a 
higher proportion of lean muscle mass is also associated 
with a higher BMI. Muscle is more insulin sensitive than 
adipose tissue and therefore is more metabolically 
favourable.29
People with a BMI within the normal range (18.5- 
24.9 kg/m2), but high body fat content (normal weight 
obesity) have higher prevalence of cardiometabolic 
dysregulation, metabolic syndrome and cardiovascular 
risk factors than those with less body fat. Among 
women, normal weight obesity (body fat >3 3.3% vs. 
< 28.9%) more than doubled the risk of cardiovascular 
mortality.44 
Furthermore, different fat compartments may 
contribute differently to CV risk. Although subcutaneous 
(peripheral) fat is not metabolically neutral, intra-
abdominal (visceral) fat correlates to a greater extent 
with metabolic abnormalities observed in overweight 
and obese subjects, is associated with more severe 
insulin resistance and may be more proatherogenic.45,46 
Indeed, cardiometabolic risk increases with increasing 
visceral adiposity and BMI, whereas increasing 
subcutaneous fat is not associated with uniform 
increases in metabolic CV risk factors. Furthermore, 
some studies have suggested that subcutaneous fat, 
at least in patients with a high amount of visceral fat 
tissue, may be metabolically beneficial, providing 
some protection against increased CV risk.47 
The relative proportions of abdominal and 
subcutaneous fat may vary from person to person. 
Even among lean individuals, those with accumulation 
of intra-abdominal fat are more insulin resistant and 
at higher risk of developing the metabolic syndrome 
and cardiovascular risk factors than those with 
subcutaneous fat deposition.48 
Body fat distribution may also differ among ethnic 
groups. For example, despite lower prevalence rates of 
generalised obesity, Asian Indians are a high risk group 
for type 2 diabetes, metabolic syndrome and coronary 
artery disease.49 This has been partly explained by 
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a tendency towards an “Asian Indian phenotype”, 
which describes central body obesity with primarily 
increased visceral fat, higher plasma insulin levels, 
insulin resistance and lower adiponectin levels.49 
This data from studies in Asian Indians suggests that 
body fat distribution, particularly visceral adiposity, is 
the principle anthropometric determinant of disease 
risk, rather than measures of whole body fat, i.e. BMI.
In patients with diabetes, weight accumulation 
related to intensive glucose control is not limited to the 
abdomen, but rather is generalised, being distributed 
between fat mass and lean mass. Furthermore, the 
increase in fat mass is predominantly peripheral rather 
than central, so it may not necessarily result in an overall 
increase in cardiovascular risk.50,51 
Reverse causation bias, trial design and different 
definitions
Reverse causation usually refers to the situation in 
which, instead of the outcome resulting from the 
risk factor, the outcome precedes the risk factor. 
For example, does obesity cause insulin resistance, 
or does insulin resistance cause obesity? However, in 
terms of weight and mortality, the term is often used 
to imply that the illness (diabetes) affects both the risk 
factor (body weight) and the outcome (mortality).40 In 
studies where BMI is measured and followed after the 
presence of diabetes, it may not be clear whether the 
weight is contributory to mortality, or coincidentally a 
symptom of the illness causing mortality. For the same 
reason, studies that measure BMI and follow patients 
from diagnosis are not comparable to studies that enrol 
patients with pre-existing diabetes and may produce 
different results.
Furthermore, it is important to distinguish between 
otherwise healthy patients with a naturally low BMI 
and patients with a low BMI consequent to weight loss 
(who may have been overweight for most of their life), 
including those with weight loss due to illness. In the 
same way, a higher BMI from natural weight gain may 
differ in outcomes from drug-related or disease-related 
weight gain, e.g. in heart failure, all of which may differ 
in outcome from long-standing obesity. Therefore, 
detailed information about life-long health status, CVD 
risk factors and prior weight changes at study baseline 
is required to fully adjust for such confounding factors. 
This explanation might also help to explain the different 
observations according to age where the obesity 
paradox appears to apply to older individuals, but is 
not apparent in younger populations.20,32 Strandberg et 
al followed up a population of men into old age for 
whom BMI and CVD risk data were available from the 
age of 25 years.52 They showed that, before midlife, 
mortality was higher among overweight compared to 
normal weight individuals. Thereafter, individuals who 
moved from overweight in midlife to normal weight had 
the highest CVD risk in midlife and the greatest total 
mortality, even after adjusting for diseases prevalent at 
midlife. In comparison, mortality risk in older age was no 
different among men with a constantly normal weight 
from midlife to old age, those who were constantly 
overweight and those who became overweight after 
midlife. They concluded that a population of people 
at old age, whether normal or overweight, is actually 
a mixture of individuals, each with a different weight 
and cardiovascular history: “Despite being a mortality 
risk factor in midlife, overweight or even obesity in late 
life may thus disguise itself as a protective factor in late 
life.” 
Statistics – index event bias
Obesity paradox studies, and especially those including 
patients who have already experienced an initial 
cardiovascular event, have a recurrence risk design. 
In other words they are selecting for a group of patients 
who have a very high risk of a repeat of the same or 
a similar outcome. Consequently, the influence of 
an individual risk factor is proportionately reduced, 
because the overall risk, i.e. the sum of the risk factors 
as a whole, plays a more dominant role. As a result, 
the association between an individual risk factor and 
recurrence of the event will be biased towards the null 
(no apparent effect) or even reversed (paradoxical 
protective effect).32,42,53
Therefore, statistically, it may appear that obesity is less 
important to cardiovascular outcomes, even though it 
remains in reality a significant modifiable risk factor. Smits 
et al recently published a simple numerical example 
of index event bias, which eloquently demonstrates its 
influence on the statistical outcome.53 
Does the obesity paradox influence the 
approach to management of patients with 
diabetes?
Regardless of the obesity paradox, in addition 
to consideration of cardiovascular risk, there is 
considerable evidence that, in patients with diabetes, 
weight loss and maintenance of a healthy weight are 
associated with improvements in glycaemic control 
and quality of life. Excess adiposity and weight gain 
in type 2 diabetes are associated with a number of 
physical and psychological consequences that affect 
adherence, response to therapy and long-term glucose 
control. Increased fat mass is associated with insulin 
resistance, which exacerbates beta-cell dysfunction 
and increases requirement for insulin and further weight 
gain.54 Higher BMI at initiation of treatment predicts a 
poorer response to insulin therapy.55,56 This may severely 
compromise the long-term outcome, where sustained 
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improvements in glycaemia have been shown to significantly 
improve microvascular complications, and the long-term risk of 
cardiovascular events.30,57,58 
Weight gain may compound feelings of depression and anxiety, 
which are already common in patients with diabetes and 
which are associated with poor adherence and self-care.59 In 
the Diabetes Attitudes Wishes and Needs (DAWN) study, which 
surveyed the perceptions surrounding diabetes care and self-
management among more than 5000 type 2 diabetics, 50% 
of patients expressed anxiety about their body weight, which 
contributed to a common poor sense of well-being.60 The fear 
of weight gain discourages both initiation of and adherence to 
insulin therapy. Patients who are concerned about weight gain 
are more likely to omit insulin doses or adjust their insulin dose 
in order to aim for higher blood glucose targets and to avoid 
normoglycaemia in an attempt to manage their body weight. 
This behaviour is associated with a significant increase in risk of 
diabetes-related emergency room visits and hospitalisations, and 
higher rates of retinopathy and neuropathy.61
In contrast, weight loss increases the chance of remission of type 
2 diabetes and reduces medication requirements. The fact that 
this is more likely to occur in newly diagnosed diabetics and those 
with better glycaemic control highlights the importance of early 
consideration of lifestyle interventions.62 Reducing medications 
may reduce costs and drug-related adverse effects, including 
hypoglycaemia.33,39,43 
In the Look AHEAD study, weight loss was safe and associated 
with a number of additional benefits, including reductions in sleep 
apnoea, urinary incontinence and depression, and improvements 
in physical functioning, mobility and quality of life.36
Conclusion
The obesity paradox is a controversial finding that has been 
observed, not only in patients with diabetes, but also associated 
with other chronic diseases. However, the mechanisms that might 
underlie the observation are not always clear and range from the 
pathology itself, to treatment modalities, study design and even 
statistical interpretation of the data.
In contrast, potential benefits of weight loss in overweight patients 
with established cardiovascular disease and/or diabetes clearly 
extend beyond estimation of cardiovascular risk, significantly 
influencing treatment choices and outcomes and the patient’s 
quality of life. Therefore, lifestyle advice, including prudent dietary 
choices, exercise, weight loss and maintenance of a healthy 
body weight should remain the cornerstone of management for 
these patients.
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